Combined influence of depressive symptoms and systemic inflammation on all-cause and cardiovascular mortality: evidence for differential effects by gender in the English Longitudinal Study of Ageing

Samantha Lawes MSc1, Panayotes Demakakos PhD1, Andrew Steptoe DSc1, Glyn Lewis PhD2 and Livia A. Carvalho PhD3

1Department of Epidemiology and Public Health, University College London, London, UK; 2Division of Psychiatry, University College London, London, UK and 3Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK

Abstract

Background. Depressive symptoms and inflammation are risk factors for cardiovascular disease (CVD) and mortality. We investigated the combined association of these factors with the prediction of CVD and all-cause mortality in a representative cohort of older men and women.

Methods. We measured C-reactive protein (CRP) and depressive symptoms in 5328 men and women aged 52–89 years in the English Longitudinal Study of Ageing. Depressive symptoms were measured using the eight-item Centre for Epidemiological Studies Depression Scale. CRP was analysed from peripheral blood. Mortality was ascertained from national registers and associations with depressive symptoms and inflammation were estimated using Cox proportional hazard models.

Results. We identified 112 CVD related deaths out of 420 all-cause deaths in men and 109 CVD related deaths out of 334 all-cause deaths in women over a mean follow-up of 7.7 years. Men with both depressive symptoms and high CRP (3–20 mg/L) had an increased risk of CVD mortality (hazard ratio; 95% confidence interval: 3.89; 2.04–7.44) and all-cause mortality (2.40; 1.65–3.48) after adjusting for age, socioeconomic variables and health behaviours. This considerably exceeds the risks associated with high CRP alone (CVD 2.43; 1.59–3.71, all-cause 1.49; 1.20–1.84). There was no significant increase in mortality risk associated with depressive symptoms alone in men. In women, neither depressive symptoms or inflammation alone or the combination of both significantly predicted CVD or all-cause mortality.

Conclusions. The combination of depressive symptoms and increased inflammation confers a considerable increase in CVD mortality risk for men. These effects appear to be independent, suggesting an additive role.

Introduction

A number of population-based studies have reported that people with depressive symptoms are at greater risk of mortality (Wulsin et al., 1999; Schulz et al., 2002; Wulsin et al., 2005; Lasserre et al., 2016), particularly from cardiovascular disease (CVD) (Laursen et al., 2007; Wu and Kling, 2016; Correll et al., 2017). Even patients with sub-clinical levels of depressive symptoms, face increased mortality risk (Russ et al., 2012). A robust literature demonstrates that depressive symptoms increase CVD risk in initially healthy people (Cuijpers and Smit, 2002; Rugglies, 2002; Wulsin and Singal, 2003; Nicholson et al., 2006; Van der Kooy et al., 2007; Gan et al., 2014) and CVD mortality in those with established disease (Barth et al., 2004; van Melle et al., 2004; Nicholson et al., 2006; Meijer et al., 2011; Meijer et al., 2013). Many studies have specifically reported an association between depressive symptoms and mortality in older people. Incident (Penninx et al., 1998; Vinkers et al., 2004; Teng et al., 2013), intermittent (Geerlings et al., 2002) and chronic depression (Geerlings et al., 2002; Schoevers et al., 2009; Teng et al., 2013) increase all-cause and CVD mortality in this age group. However, these findings are not entirely consistent, with some studies reporting no association (Callahan et al., 1998; Cuijpers, 2001; Hybels et al., 2002; McCusker et al., 2006). Both persistence and severity of depressive symptoms are associated with increased mortality risk in older people (White et al., 2015, 2016).

Extensive evidence also exists for an association between depressive symptoms and inflammation (Raison et al., 2006; Irwin and Miller, 2007; Miller et al., 2009; Miller and Raison,
Longitudinal studies have reported an association between depressive symptoms and inflammatory biomarkers in otherwise healthy people (Gimeno et al., 2009; Hamer et al., 2009; Copeland et al., 2012; Au et al., 2015; Zalli et al., 2015; Bell et al., 2017). In addition, several meta-analyses show higher levels of inflammation in depressed patients compared with healthy controls (Howren et al., 2009; Dowlati et al., 2010; Liu et al., 2012; Valkanova et al., 2013; Eyre et al., 2016). A recent cumulative meta-analysis confirmed the robust nature of the depression–inflammation relationship, showing evidence of increased circulating interleukin-6 and C-reactive protein (CRP) in depressed compared with non-depressed individuals (Haapakoski et al., 2015). In patients with CVD, the prevalence of depression is four times higher than in people from the general population (Thombs et al., 2006). Depression also shows a high co-morbidity with a number of major chronic inflammatory or autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis and diabetes type 1 and 2 (Maes et al., 2012). However, it is unclear whether the increased mortality risk in depressed people is due to inflammation.

In light of the well-established role of inflammatory processes in both the pathogenesis of atherosclerosis and the prediction of cardiac events (Shimbo et al., 2005; Golia et al., 2014; Biasucci et al., 2017), it has been proposed that inflammation may be mediating the association between depression and mortality, particularly in relation to CVD. However, evidence linking inflammation and depressive symptoms with the development of CVD is inconsistent. A population-based study reported that depressed symptoms and CRP interact in the prediction of coronary heart disease (CHD) in men (Ladwig et al., 2005). However, other studies have demonstrated that depressive symptoms increase CVD risk independently of inflammatory biomarkers (Empana et al., 2005; Nabi et al., 2008; Surtess et al., 2008; Davidson et al., 2009; Hamer et al., 2011), whilst several studies have reported minimal effects of mediation (Vaccarino et al., 2007; Kop et al., 2010; Hiles et al., 2015; Hughes et al., 2016). To our knowledge, only one study has investigated the combined effect of depressive symptoms and elevated inflammation on CVD development. Ladwig et al. (2005) showed that combined depressed mood and high CRP (>3 mg/L) conferred a significantly greater risk of future cardiac events than either depressed mood or high CRP alone in older men.

Gender differences have also been observed in the association between late-life depression and mortality. Several studies report a greater mortality risk in men (Anstey and Luszcz, 2002; Ryan et al., 2008; Jeong et al., 2013; Diniz et al., 2014), particularly for incident depression (Teng et al., 2013) and CVD (Penninx et al., 1998; Wulsin et al., 1999); whilst women appear to have increased mortality risk in the presence of chronic or severe depressive symptoms (Ryan et al., 2008; Teng et al., 2013). An emerging literature also suggests women are more likely to present with inflammation when depressed (Bell et al., 2017), potentially due to higher reactivity to stressful stimuli (Piccinelli and Wilkinson, 2000). Whether the inflammation and depression link is particularly important for women is still unknown.

In this study, we used data from the English Longitudinal Study of Ageing (ELSA) to investigate the combined effects of depressive symptoms and inflammation on CVD and all-cause mortality risk in older men and women. In particular, we sought to investigate whether depressive symptoms moderate the mortality risk associated with increased inflammation or whether inflammation could be mediating the association between depressive symptoms and mortality. In light of previous findings, we hypothesise that people with both depressive symptoms and inflammation will have significantly greater mortality risk than people with depressive symptoms or inflammation alone.

### Materials and methods

#### Study population

The ELSA is a prospective study of a representative sample of community-dwelling people aged 50 and over living in England. It collects health, social and economic data. The study commenced in 2002, and the sample has been followed up every 2 years. Data are collected using computer-assisted personal interviews and self-completion questionnaires, with additional nurse visits for the assessment of biomarkers every 4 years. Wave 1 included a baseline interview and took place in 2002–2003. Wave 2 took place in 2004–2005 and consisted of an interview and a health examination that included a collection of blood samples. At wave 1, the sample consisted of 11391 study members and was deemed to be nationally representative. For more information on ELSA see [http://www.elsa-project.ac.uk/](http://www.elsa-project.ac.uk/).

Our study included 5328 people, aged 52–89 years, from an initial cohort of 8670 who participated in the interview at wave 2. We excluded 1084 individuals who did not participate in the health examination survey, 134 who did not consent for their vital status data to be included, 1411 who were unable to provide a blood sample and 330 individuals whose CRP values were unavailable or not reliable. The latter included samples which were lost in the post, received later than 5 days after collection, considered unusable by the laboratory or of insufficient amount to be analysed. Detailed information about how the ELSA data were collected and processed into their current format and about how each variable was coded is available at [https://discove.ukdataservice.ac.uk/series/?sn=200011](https://discove.ukdataservice.ac.uk/series/?sn=200011). We also excluded 155 participants from the analysis because their CRP levels were $\geq 20$ mg/L, allowing for the elimination of individuals with acute inflammation, while another 229 participants were excluded because of missing values in the covariates.

Participants included and excluded from the analysis did not differ significantly in terms of sex. The group included in the analysis was younger, less likely to be depressed, more likely to be married, more educated and wealthier than the group who was excluded.

#### Assessment of inflammation

Blood samples were taken by the study nurse at wave 2 and serum CRP was analysed by Royal Victoria Infirmary, Newcastle. High sensitivity plasma CRP level was dichotomised into two categories: $<3$ mg/L was defined as normal and 3–20 mg/L was defined as high. This cut off point is based on guidelines from the Centre for Disease Control and Prevention and the American Heart Association, suggesting that plasma CRP values of $>3.0$ mg/L might be predictive of CVD (Pearson et al., 2003).

#### Assessment of depressive symptoms

Depressive symptoms were measured at wave 2 (2004–2005) using the eight-item Centre for Epidemiological Studies Depression Scale 8 (CES-D8) which is a self-report questionnaire designed to measure depressive symptomatology in the general population.
(Radloff, 1977). Respondents were asked how often they felt depressed, felt that everything was an effort, slept restlessly, were happy, felt lonely, enjoyed life, felt sad, and could not go going. The two positive items (‘was happy’ and ‘enjoyed life’) are reverse coded, so a higher score here also indicates a more depressed mood. We subsequently derived a summary CES-D score by adding responses to all eight dichotomous questions (possible range: 0–8). The exact wording of the different items can be found in appendix 1. The eight-item abbreviated version of the CES-D has been widely used, is internally consistent, has been validated in both the general population (Van de Velde et al., 2009) and older adults, and shows a comparable construct of depression across 11 different countries (Missinne et al., 2014). The presence of depressive symptoms was defined as CES-D ≥4 as per previous publications (Steffick, 2000; Hamer et al., 2012; Mhaoláin et al., 2012; Demakakos et al., 2013; Malgaroli et al., 2017). This conservative threshold has been found to produce comparable results to the ≥16 cut off on the well-validated 20-item CES-D scale (Radloff, 1977; Steffick, 2000).

Depressive symptoms and inflammation as a combined variable

In order to ascertain whether the combination of depressive symptoms and inflammation predicts mortality, the variables based on wave 2 assessments were combined and four new variables were computed: ‘no depressive symptoms/low inflammation’, ‘no depressive symptoms/high inflammation’, ‘depressive symptoms/low inflammation’ and ‘depressive symptoms/high inflammation’.

Mortality

Mortality was ascertained for a mean 7.7 year period for consenting study members (5328) by linking to the UK National Health Service mortality register up until 12 November 2015. In England, all deaths need to be registered within 5 days, therefore participants not registered as dead were assumed to be alive. Deaths were classified according to International Classification of Diseases (ICD) 10th Edition. Deaths with ICD10 codes 100 to 199 were classified as cardiovascular deaths.

Covariates

All covariates were collected at wave 2 (2004–2005) with the exception of education and sex which were collected at wave 1. All covariates where determined by self-report, with the exception of body mass index (BMI). Age was treated as a continuous variable. Socioeconomic status (SES) was operationalised by using marital status (married/cohabiting v. not married/single/divorced), level of education (degree/higher/A-level, GCSE/O-level/other, no qualifications) and total wealth in tertiles. Total wealth was defined from the sum of financial, physical (e.g. businesses, land) and housing wealth, minus debts and pension payments. Health behaviours included: smoking (never smoked, ex-smoker, current smoker) and BMI (<25 kg/m², 25–29.99 kg/m², >30 kg/m²) (Banks et al., 2006). The presence of chronic diseases were added as separate variables and defined as yes/no. They were calculated as lifetime self-reported physician diagnoses of chronic conditions (i.e. CVD (myocardial infarction and stroke), chronic lung disease, cancers (of any site) and emotional, nervous and psychiatric problems).

The covariates have been included because they have all been shown to be associated with mortality and are therefore potential confounders (Marmot et al., 2012; Wong, 2014; Pletcher and Moran, 2017). Furthermore, health behaviours such as smoking and BMI were included as they have been shown to mediate the relationship between depression and mortality (Joynt et al., 2003).

Statistical analysis

Differences between the characteristics of the participants included and excluded from the analysis were analysed. Baseline characteristics were analysed by depressive symptoms and inflammation levels. The association of depressive symptoms and inflammation levels (separately and in combination) with CVD and all-cause mortality were assessed by Cox proportional hazards regression models. The proportionality assumption was tested using Nelson–Aalen cumulative hazard curves and Schoenfeld residuals. We inspected the plots and the global test (p = 0.8052) confirming that we do not have a violation of the proportional assumption. Survival time was measured in months, from the date of interview in wave 2 (2004–2005) to the date of death or 12 November 2015, whichever was first. Kaplan Meier survival curves are available online (online Supplementary Fig. S1).

We investigated whether there were significant interactions between age or sex and depression/inflammation categories in order to determine whether the association between depression/inflammation levels and mortality varied according to age or between men and women. We used the likelihood ratio test to compare the goodness of fit of a stratified model. We found no interaction between sex and depressive symptoms, however, we did find that the association between inflammation and mortality varied significantly by sex (p value = 0.013). There was also an age interaction between inflammation and mortality, however, this disappeared once we stratified our analysis by sex, therefore, we only present the sex-stratified analyses. We first fitted a basic unadjusted model, which was followed by an age-adjusted model. We then additionally adjusted for socioeconomic variables, health behaviours and chronic diseases.

To investigate moderation we tested whether a multiplicative interaction between depressive symptoms and inflammation was significantly associated with mortality. To investigate mediation, we first examined the association between depressive symptoms and mortality and then added inflammation to see how much of the association was explained. All analyses were performed using STATA 13.0 (StataCorp LP, College Station Texas).

Results

There were 420 all-cause male deaths (including 112 CVD related) over mean of 7.6 years follow-up and 334 all-cause female deaths (including 109 CVD related) over a mean of 7.8 years follow-up. Out of a total of 5328 people, we identified 420 all-cause deaths in men and 334 in women during 18 594 and 22 519 person-years, respectively.

Table 1 represents social-demographic characteristics in depression/inflammation categories in men and women separately. Men and women with concurrent depressive symptoms and high inflammation were more likely to be poorer, less educated, more likely to smoke, have a higher BMI and were more likely to have chronic lung disease and emotional, nervous and psychiatric problems. There were no significant overall differences.
<table>
<thead>
<tr>
<th></th>
<th>No depressive symptoms/normal CRP</th>
<th>No depressive symptoms/high CRP</th>
<th>Depressive symptoms/normal CRP</th>
<th>Depressive symptoms/high CRP</th>
<th>p value</th>
<th>No depressive symptoms/normal CRP</th>
<th>No depressive symptoms/high CRP</th>
<th>Depressive symptoms/normal CRP</th>
<th>Depressive symptoms/high CRP</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number</strong></td>
<td>1551</td>
<td>668</td>
<td>132</td>
<td>98</td>
<td></td>
<td>1542</td>
<td>864</td>
<td>275</td>
<td>198</td>
<td></td>
</tr>
<tr>
<td><strong>Mean age (SD) (years)</strong></td>
<td>64.9 (8.8)</td>
<td>67 (9.1)</td>
<td>64.5 (9.1)</td>
<td>66.9 (9.9)</td>
<td>&lt;0.001</td>
<td>65 (9.0)</td>
<td>66.5 (9.2)</td>
<td>67.3 (10.3)</td>
<td>67.4 (9.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Marital status (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>1252 (80.7)</td>
<td>501 (75)</td>
<td>79 (59.9)</td>
<td>60 (61)</td>
<td>&lt;0.001</td>
<td>1023 (66.3)</td>
<td>530 (61.3)</td>
<td>128 (46.6)</td>
<td>83 (41.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Not married</td>
<td>299 (19.3)</td>
<td>167 (25)</td>
<td>53 (40)</td>
<td>38 (39)</td>
<td></td>
<td>519 (33.7)</td>
<td>334 (38.7)</td>
<td>147 (53.5)</td>
<td>115 (58.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Education (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Degree/Higher/A-level</td>
<td>700 (45.1)</td>
<td>228 (34.1)</td>
<td>43 (32.6)</td>
<td>27 (27.6)</td>
<td>&lt;0.001</td>
<td>458 (29.7)</td>
<td>191 (22.1)</td>
<td>51 (18.6)</td>
<td>39 (19.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>GCSE/O-level/Other qualification</td>
<td>444 (28.6)</td>
<td>203 (30.4)</td>
<td>37 (28)</td>
<td>27 (27.6)</td>
<td></td>
<td>555 (36)</td>
<td>281 (32.5)</td>
<td>98 (35.6)</td>
<td>53 (26.8)</td>
<td></td>
</tr>
<tr>
<td>No qualification</td>
<td>407 (26.2)</td>
<td>237 (35.5)</td>
<td>52 (39.4)</td>
<td>44 (44.9)</td>
<td></td>
<td>529 (34.3)</td>
<td>392 (45.4)</td>
<td>126 (45.8)</td>
<td>106 (53.54)</td>
<td></td>
</tr>
<tr>
<td><strong>Total wealth (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richest</td>
<td>688 (44.4)</td>
<td>203 (30.4)</td>
<td>40 (30.3)</td>
<td>17 (17.4)</td>
<td>&lt;0.001</td>
<td>681 (44.2)</td>
<td>228 (26.4)</td>
<td>73 (26.6)</td>
<td>28 (14.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intermediate</td>
<td>531 (34.2)</td>
<td>252 (37.7)</td>
<td>35 (26.5)</td>
<td>35 (37.5)</td>
<td></td>
<td>486 (31.5)</td>
<td>323 (37.4)</td>
<td>89 (32.4)</td>
<td>82 (41.4)</td>
<td></td>
</tr>
<tr>
<td>Poorest</td>
<td>332 (21.4)</td>
<td>213 (31.9)</td>
<td>57 (43.2)</td>
<td>46 (46.9)</td>
<td></td>
<td>375 (24.3)</td>
<td>313 (36.2)</td>
<td>113 (41.1)</td>
<td>88 (44.4)</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking status (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never a smoker</td>
<td>496 (32)</td>
<td>149 (22.3)</td>
<td>34 (25.8)</td>
<td>15 (15.3)</td>
<td>&lt;0.001</td>
<td>743 (48.2)</td>
<td>379 (43.9)</td>
<td>107 (38.9)</td>
<td>65 (32.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>894 (57.6)</td>
<td>383 (57.3)</td>
<td>73 (55.3)</td>
<td>57 (58.2)</td>
<td></td>
<td>634 (41.1)</td>
<td>355 (41.1)</td>
<td>126 (45.8)</td>
<td>79 (39.9)</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>161 (10.4)</td>
<td>136 (20.4)</td>
<td>25 (18.9)</td>
<td>26 (26.5)</td>
<td></td>
<td>165 (10.7)</td>
<td>130 (15.1)</td>
<td>42 (15.3)</td>
<td>54 (27.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Body Mass Index</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;25 kg/m² (%)</td>
<td>403 (26.8)</td>
<td>123 (19.3)</td>
<td>35 (27.8)</td>
<td>20 (23.5)</td>
<td>&lt;0.001</td>
<td>606 (40.5)</td>
<td>121 (14.9)</td>
<td>98 (37)</td>
<td>32 (17.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>25–29.99 kg/m² (%)</td>
<td>777 (51.7)</td>
<td>306 (48.1)</td>
<td>59 (46.8)</td>
<td>32 (37.7)</td>
<td></td>
<td>628 (42)</td>
<td>285 (35)</td>
<td>113 (42.6)</td>
<td>65 (35.5)</td>
<td></td>
</tr>
<tr>
<td>&gt;30 + kg/m² (%)</td>
<td>323 (21.5)</td>
<td>207 (32.6)</td>
<td>32 (25.4)</td>
<td>33 (38.8)</td>
<td></td>
<td>262 (17.5)</td>
<td>408 (50.1)</td>
<td>54 (20.4)</td>
<td>86 (47)</td>
<td></td>
</tr>
<tr>
<td><strong>Chronic disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVD (% yes)</td>
<td>115 (7.41)</td>
<td>61 (9.13)</td>
<td>14 (10.61)</td>
<td>14 (14.29)</td>
<td>0.052</td>
<td>48 (3.11)</td>
<td>31 (3.59)</td>
<td>14 (5.09)</td>
<td>14 (7.07)</td>
<td>0.026</td>
</tr>
<tr>
<td>Cancer (% yes)</td>
<td>85 (5.48)</td>
<td>46 (6.89)</td>
<td>7 (5.30)</td>
<td>11 (11.22)</td>
<td>0.093</td>
<td>139 (9.01)</td>
<td>58 (6.73)</td>
<td>26 (9.49)</td>
<td>14 (7.07)</td>
<td>0.191</td>
</tr>
<tr>
<td>Lung diseasea (% yes)</td>
<td>78 (5.03)</td>
<td>70 (10.48)</td>
<td>10 (7.58)</td>
<td>18 (18.37)</td>
<td>&lt;0.001</td>
<td>55 (3.57)</td>
<td>69 (8.00)</td>
<td>31 (11.31)</td>
<td>33 (16.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Psychiatricb (% yes)</td>
<td>81 (5.22)</td>
<td>32 (4.79)</td>
<td>25 (18.94)</td>
<td>22 (22.45)</td>
<td>&lt;0.001</td>
<td>159 (10.31)</td>
<td>81 (9.40)</td>
<td>58 (21.17)</td>
<td>51 (25.76)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

SD = standard deviation. Statistical tests examined the associations of demographic variables with depressive symptoms/inflammation levels. ANOVA tests were used for continuous variables and Chi-square tests were used for categorical variables.

aChronic lung disease.
bEmotional, nervous or psychiatric diseases.
in the frequency of CVD or cancer between depression/inflammation levels in either men or women. (Table 1).

**Depressive symptoms and inflammation as a combined predictor of CVD mortality**

In men, depressive symptoms alone were not associated with any significant increase in the risk of death, whilst high inflammation was associated with a 238% (HR: 3.38; 95% CI 2.23–5.10) increased risk. Men with both depressive symptoms and high inflammation had a 584% (HR: 6.84; 95% CI 3.71–12.6) increased CVD mortality risk. This association remained significant after adjustment for age, SES and health behaviours, with men who had both depressive symptoms and high inflammation demonstrating a 289% (HR: 3.89; 95% CI 2.04–7.44) increased risk of death (p value <0.001) (Table 2 and Fig. 1). In women, the associations were more modest and failed to reach significance (Table 2).

**Depressive symptoms and inflammation as a combined predictor of all-cause mortality**

In men, the direction of results was similar for all-cause mortality. Depressive symptoms alone were not associated with a significant increase in the risk of death, whilst high inflammation was associated with a 91% (HR: 1.91; 95% CI 1.55–2.36) increased risk, compared with men with neither. Men with both depressive symptoms and high inflammation had a 241% (HR: 3.41; 95% CI 2.39–4.86) increased mortality risk. This association was attenuated after adjustment for age, SES and smoking. However, the association remained significant, with men who had both depressive symptoms and high inflammation demonstrating a 140% (HR: 2.40; 95% CI 1.65–3.48) increased risk of death (Fig. 1).

The results for women were different. In the unadjusted model, both depressive symptoms and high inflammation separately increased the risk of death by 85% (HR: 1.85; 95% CI 1.32–2.59) and 48% (HR: 1.48; 95% CI 1.16–1.90), respectively. The combination of both depressive symptoms and high inflammation increased the risk to 89% (HR: 1.89; 95% CI 1.29–2.76), only marginally more than depressive symptoms alone. The increased risk of depressive symptoms and high inflammation to all-cause mortality in women was explained by age as after adjustments the risk was no longer significant (Table 2).

**Effects of moderation and mediation**

Moderation analysis showed that an interaction term of depressive symptoms by inflammation was not significantly associated with mortality in all categories: all-cause mortality in men (p = 0.426); all-cause mortality in women (p = 0.155); CVD mortality in men (p = 0.868) and CVD mortality in women (p = 0.481). This suggests that the mortality risk conferred by increased levels of inflammation is not further augmented by depressive symptoms.

Mediation analysis showed that the strength of the association between depressive symptoms and mortality was not reduced by including inflammation, suggesting a direct effect of depressive symptoms on mortality risk (online Supplementary Table S1).

**Discussion**

In this study, we examined the combined effect of depressive symptoms and inflammation on CVD and all-cause mortality in a large cohort of older adults. Our findings suggest that older men, with both depressive symptoms and high levels of inflammation, have an increased risk of CVD and all-cause mortality compared with men with depressive symptoms or inflammation alone. In addition, our study demonstrates the independent effects of depressive symptoms and inflammation on mortality, finding no evidence of either moderation or mediation. To our knowledge, our study is the first to investigate the combined effect of depressive symptoms and inflammation of mortality in both men and women.

**Depression, inflammation and mortality**

We demonstrated an increased risk of all-cause mortality in the comparison between men with high and low baseline levels of inflammation. The addition of depression to the model increased the risk substantially suggestive of a particularly high-risk phenotype in men. This supports findings in healthy, older men showing that high inflammation predicted cardiovascular events only in people with depressed mood (Ladwig et al., 2005). These findings suggest that depression and inflammation might cause CVD through separate physiological pathways, such as elevated interleukin-6 upstream of CRP (Ridker, 2016), triglycerides (Parekh et al., 2017), cortisol as a result of stress-induced hyperactivity of the hypothalamic-pituitary-adrenal axis (Jokinen and Nordstrom, 2009), endothelial dysfunction (Chen et al., 2011) and platelet activation (Williams et al., 2014).

Our study found no significant interaction between depressive symptoms and inflammation on mortality and no effect of mediation, a finding which is supported by other studies but not by all. To our knowledge, there is only one other study which looked at the potential synergistic effect of depressive symptoms and inflammation in the prediction of cardiovascular events. Ladwig showed a significant interaction between depressive symptoms and inflammation in the prediction of cardiovascular events, suggesting a shared underlying mechanism (Ladwig et al., 2005). These authors, however, have only investigated men.

Most previous studies investigating the effects of inflammation mediating the association between depression and all-cause or CVD mortality showed either no or small effects. Similar to our study, Empana et al., (2005) showed that men with depressive symptoms had a 53% increase in the odds of CHD and the association remained unchanged when inflammatory markers were added to the model. Davidson et al., 2009 found that depressive symptoms increased the risk of incident CHD; this risk was not explained by increased inflammation in either men or women. Nabi et al., 2008 also found an association between psychological distress and incident CHD which remained after adjustment for inflammatory markers. Contrary to our study and the studies cited above, there has also been reports of mediation. Hughes et al., (2016) reported an association between depressive symptoms and all-cause mortality which was partly explained by inflammation (CRP 7.3%). Inflammation partly mediated the predictive value of depressive symptoms by 6.5% in cardiovascular mortality risk (Kop et al., 2010), and by 8.1% in cardiovascular hospitalization (Hiles et al., 2015). This supports the knowledge that other pathways are also involved in the depression and mortality link.

**Effect of gender on the link between depressive symptoms, inflammation and mortality**

Clear sex-specific differences were observed in the inter-relationships of depressive symptoms, inflammation and
Table 2. Association between depressive symptoms/inflammation levels and all-cause and cardiovascular mortality by sex

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th></th>
<th>Women</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No depressive symptoms</td>
<td>Depressive</td>
<td>No depressive</td>
<td>Depressive</td>
</tr>
<tr>
<td></td>
<td>normal/normal CRP</td>
<td>symptoms/high CRP</td>
<td>symptoms/normal CRP</td>
<td>symptoms/high CRP</td>
</tr>
<tr>
<td>Model 1 HR (95%</td>
<td>1.00 (reference)</td>
<td>1.91 (1.55–2.36)</td>
<td>1.42 (0.93–2.17)</td>
<td>3.41 (2.39–4.86)</td>
</tr>
<tr>
<td>CI, p values)a</td>
<td>&lt;0.001</td>
<td>0.104</td>
<td>&lt;0.001</td>
<td>&gt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 2 HR (95%</td>
<td>1.00 (reference)</td>
<td>1.63 (1.32–2.00)</td>
<td>1.47 (0.97–2.25)</td>
<td>3.03 (2.12–4.32)</td>
</tr>
<tr>
<td>CI, p values)a</td>
<td>&lt;0.001</td>
<td>0.072</td>
<td>&lt;0.001</td>
<td>&gt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 3 HR (95%</td>
<td>1.00 (reference)</td>
<td>1.54 (1.25–1.90)</td>
<td>1.29 (0.84–1.98)</td>
<td>2.59 (1.80–3.74)</td>
</tr>
<tr>
<td>CI, p values)c</td>
<td>&lt;0.001</td>
<td>0.242</td>
<td>&lt;0.001</td>
<td>&gt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 4 HR (95%</td>
<td>1.00 (reference)</td>
<td>1.49 (1.20–1.84)</td>
<td>1.27 (0.83–1.96)</td>
<td>2.40 (1.65–3.48)</td>
</tr>
<tr>
<td>CI, p values)d</td>
<td>&lt;0.001</td>
<td>0.273</td>
<td>&lt;0.001</td>
<td>&gt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 5 HR (95%</td>
<td>1.00 (reference)</td>
<td>1.46 (1.18–1.81)</td>
<td>1.24 (0.80–1.90)</td>
<td>2.09 (1.43–3.07)</td>
</tr>
<tr>
<td>CI, p values)e</td>
<td>&lt;0.001</td>
<td>0.337</td>
<td>&lt;0.001</td>
<td>&gt;0.001</td>
</tr>
<tr>
<td>All-cause</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1 HR (95%</td>
<td>3.38 (2.23–5.10)</td>
<td>1.86 (0.79–4.38)</td>
<td>6.84 (3.71–12.6)</td>
<td>1.00 (0.159</td>
</tr>
<tr>
<td>CI, p values)a</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 2 HR (95%</td>
<td>2.81 (1.86–4.26)</td>
<td>1.91 (0.81–4.51)</td>
<td>5.78 (3.13–10.68)</td>
<td>1.00 (0.140</td>
</tr>
<tr>
<td>CI, p values)a</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 3 HR (95%</td>
<td>2.56 (1.68–3.89)</td>
<td>1.51 (0.63–3.62)</td>
<td>4.50 (2.39–8.47)</td>
<td>1.00 (0.354</td>
</tr>
<tr>
<td>CI, p values)c</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 4 HR (95%</td>
<td>2.43 (1.59–3.71)</td>
<td>1.50 (0.63–3.60)</td>
<td>3.89 (2.04–7.44)</td>
<td>1.00 (0.361</td>
</tr>
<tr>
<td>CI, p values)d</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 5 HR (95%</td>
<td>2.42 (1.58–3.69)</td>
<td>1.44 (0.60–3.46)</td>
<td>3.25 (1.66–6.40)</td>
<td>1.00 (0.413</td>
</tr>
<tr>
<td>CI, p values)e</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>disease mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1 HR (95%</td>
<td>3.86 (2.32–6.37)</td>
<td>2.08 (0.95–4.56)</td>
<td>6.54 (3.38–12.8)</td>
<td>1.00 (0.159</td>
</tr>
<tr>
<td>CI, p values)a</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 2 HR (95%</td>
<td>2.70 (1.70–4.08)</td>
<td>1.81 (0.84–3.92)</td>
<td>5.25 (2.74–9.64)</td>
<td>1.00 (0.134</td>
</tr>
<tr>
<td>CI, p values)a</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 3 HR (95%</td>
<td>2.47 (1.52–4.01)</td>
<td>1.57 (0.71–3.43)</td>
<td>4.13 (2.15–7.96)</td>
<td>1.00 (0.353</td>
</tr>
<tr>
<td>CI, p values)c</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 4 HR (95%</td>
<td>2.35 (1.48–3.73)</td>
<td>1.46 (0.67–3.23)</td>
<td>3.21 (1.63–6.33)</td>
<td>1.00 (0.365</td>
</tr>
<tr>
<td>CI, p values)d</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
<tr>
<td>Model 5 HR (95%</td>
<td>2.33 (1.47–3.70)</td>
<td>1.44 (0.65–3.24)</td>
<td>3.15 (1.61–6.17)</td>
<td>1.00 (0.402</td>
</tr>
<tr>
<td>CI, p values)e</td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td>(reference)</td>
</tr>
</tbody>
</table>

HR = hazard ratio; CI = confidence interval; CRP = C-reactive protein. Cox regression survival analysis models, stratified by sex, are adjusted as follows:

- Inflammation and depressive symptoms as main effects.
- As model 1, plus adjustment for age.
- As model 2, plus adjustment for socioeconomic variables (marital status, level of education, total wealth).
- As model 3, plus adjustment for health behaviours (smoking, body mass index).
- As model 4, plus individually adjustment for chronic diseases (cardiovascular disease, cancers, chronic lung disease and emotional, nervous and psychiatric problems).
mortality in this study. The combination of depressive symptoms and inflammation only conferred an increased mortality risk in men. A previous population cohort study investigating inflammation and mortality also showed sex differences. Ahmadi-Abhari et al., reported that high levels of CRP increased mortality risk in men at lower clinical threshold categories than in women, most notably for CVD mortality (2013). A similar trend has also been observed in the development of CHD. In a study of older men and women, Cushman et al. showed that the presence of high inflammation was predictive of CHD in men with intermediate Framingham Risk Scores, whereas it only became predictive of CHD in women with a high Framingham risk (2005). Furthermore, a large meta-analysis showed that inflammation only discriminated 10-year risk of cardiovascular events in men, but not in women (Kaptoge et al., 2012). Some reports on the association between depression and inflammation also support our findings, although not all. Two large population cohort studies have shown that major depression/depressive symptoms and inflammation are more strongly associated in men than in women (Ford and Erlinger, 2004; Elovinio et al., 2009). However in contrast, in a study of 508 healthy adults, depressive symptoms were only associated with inflammation in women, not in men (Ma et al., 2010). Furthermore, a study of women with suspected coronary ischemia demonstrated a robust association between depressive symptoms and inflammation which was not explained by CVD risk factors (Vaccarino et al., 2007).

Further speculation on gender differences is inspired by a recent review by Raison and Miller (2017). The authors propose that in evolutionary terms, depression may have provided an adaptive advantage to women. Inflammation was detrimental to fertility in ancestral environments (Van Bodegom et al., 2007; Schaller and Park, 2011; Kobayashi et al., 2013). Depressive symptoms promoted sickness behaviors (e.g. lethargy, psychomotor slowing and social withdrawal) which provided increased protection against pathogens (e.g. by conserving energy for an immune response), thereby reducing the need for a high inflammatory response. This is supported by findings which show that women demonstrate increased levels of depression in response to inflammatory challenge compared with men (Moieni et al., 2015; Udina et al., 2012). If women are more likely to develop depression in response to immune activation then it is possible that the presence of depressive symptoms is likely to reflect less severe underlying biological patholgy compared with men and consequently lower mortality risk. Whilst this explanation is intuitively appealing, further research is required to confirm gender specific immune mechanisms in depression.

Another possible explanation for our observed sex differences is the influence of sex hormones, particularly the protective effect of oestrogen on the heart. In people under 75, the incident of cardiovascular-related death is lower in women than in men (British Heart Foundation, 2014), with the development of atherosclerosis occurring post menopause in 95% of women (Fairweather, 2014). Even at 65–74 years of age, almost two decades after the average occurrence of menopause, women have a substantially lower incidence of CVD compared with men. This suggests that former exposure to endogenous estrogen may be atheroprotective long after menopause. Women have also been shown to have longer telomeres than men (Gardner et al., 2014). Shorter telomeres have been associated with early death in the general population (Weischer et al., 2012) although findings are inconsistent (Bojesen, 2013). Telomere length has been more robustly associated with CHD, independently of traditional vascular risk factors (Haycock et al., 2014). It is not yet understood exactly why women differ from men in the development of CHD, however to date women have been underrepresented in cardiovascular trials, resulting in a bias towards factors which are relevant to disease aetiology in men (Fairweather, 2014).

Current National Institute for Health and Clinical Excellence (NICE) guidelines recommend the use of the QRISK2 risk assessment tool to assess risk for the primary prevention of CVD in both men and women up to 84 years (National Institute for Health and Care Excellence, 2014). There has been some debate as to whether or not the addition of circulating inflammatory markers, such as CRP, should now be included in screening measures for cardiovascular risk (Pearson et al., 2003; Peters et al., 2013). The main uncertainty seems to be whether the modest increases in risk associated with higher inflammation can produce significant health benefits. This is understandable when considering that population studies have shown that CRP is a relatively moderate predictor of CVD risk, yielding an odds ratio of 1.5 when comparing the top baseline tertile with the bottom (Danesh et al., 2004). In addition, when compared with traditional risk factors, such as smoking and total cholesterol, CRP only slightly improved their predictive value. Our study demonstrates that men with comorbid depressive symptoms and high inflammation constitute a clinically meaningful risk category. In light of
these findings, it might be worth considering inflammation as a cardiovascular risk factor in depressed men. This could help identify patients who may benefit from targeted prophylactic intervention, improving screening efficacy and cardiovascular outcomes.

Study strengths and limitations

The strengths of our study include the prospective design, the presence of both women and men and the nationally representative nature of the ELSA cohort. Despite this, our study also has limitations. The first limitation of this study is that we measured depressive symptoms and inflammation at only one-time point at wave 2 (2004–2005) and did not investigate any change in levels at a later point. This design was chosen in order to maximise the number of participants with inflammation and depressive symptoms at baseline and to allow a longer follow-up period to capture mortality.

Nevertheless, we did not find an association of depressive symptoms and mortality in the absence of inflammation. In a recent study using the same cohort, which considered depressive symptoms across several years, a dose-response association was observed between persistence of depressive symptoms across time and mortality risk (White et al., 2016). Similar to these findings, data from the Longitudinal Aging Study Amsterdam also found that transient depressive episodes did not predict mortality although chronic depression did (Geerlings et al., 2002). Secondly, we also did not control for medication use in our analysis, as this data was not available. Statins, for example, present anti-inflammatory effects (Antonopoulos et al., 2012) and therefore medication use may have interfered with current findings. Thirdly, our study had a smaller proportion of female deaths compared to male deaths and therefore it is unclear whether our lack of association in women reflects an absence of an effect or is a result of insufficient power. The only closest previous study to date investigated combined depressive symptoms and inflammation in the development of CVD and was restricted to men. Finally, in our study depressive symptoms were measured by an 8 item self-reported questionnaire, rather than a diagnostic interview. Short scales such as this have previously been criticised for a lack of specificity. To address this, we defined depressive symptoms using a conservative cut-off of 4, which increases the measure’s ability to discriminate between true and false positives.

In conclusion, we demonstrated that men with concurrent depressive symptoms and increased inflammation constitute a high-mortality risk phenotype. This risk is particularly high for cardiovascular-related death. These findings have clinical implications for the treatment and prevention of depression and inflammation in men. Subgroups of depressed individuals with comorbid inflammation may benefit from additional anti-inflammatory pharmacotherapy. Further research is needed to investigate whether combined interventions improve outcomes.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S003329171800209X

Acknowledgements. Livia A. Carvalho is funded by the MRC Immunopsychiatry Consortium (RG71546).

Conflict of interest. None.

References


and symptom severity in late-life depression on the risk of all-cause mortality: the Bambui Cohort Study of Aging. Depression and Anxiety 31, 787–795.


Liu Y, Ho RC and Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 15 Apr 2019 at 08:26:08, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S003329171800209X


Ridker PM (2016) From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. *Circulation Research* 118, 145–156.


